Market Size of North America Kidney Cancer Therapeutics & Diagnostics Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
Historical Data Period | 2019 - 2022 |
CAGR | 5.80 % |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
North America Kidney Cancer Therapeutics & Diagnostics Market Analysis
The North America Kidney Cancer Therapeutics & Diagnostics Market is expected to register a CAGR of 5.8% during the forecast period. The major factors driving the growth of the market in the North America region is due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.
According to GLOBOCAN 2018, in 2018, there were about 60,336 new kidney cancer cases and the mortality was approximately 15,333 cases in the United States.
Furthermore, changes in lifestyle, excessive smoking, increased consumption of alcohol, and a rise in obesity because of sedentary life routines lead to the growing incidence of the disease. Thus, owing to the above factors the North America kidney cancer therapeutics & diagnostics market is expected to significant growth over the forecast period.